An incomplete view of the mechanisms that drive metastasis, the primary cause of cancer-
related death, has been a major barrier to development of effective therapeutics and …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

Malignant transformation can result in melanoma cells that resemble different stages of their
embryonic development. Our gene expression analysis of human melanoma cell lines and …

The intratumor microenvironment generates phenotypically distinct but interconvertible
malignant cell subpopulations that fuel metastatic spread and therapeutic resistance …

Abstract Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein
kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune checkpoint …

Epithelial‐to‐mesenchymal transition (EMT), a process through which epithelial tumor cells
acquire mesenchymal phenotypic properties, contributes to both metastatic dissemination …

Phenotypic and metabolic heterogeneity within tumors is a major barrier to effective cancer
therapy. How metabolism is implicated in specific phenotypes and whether lineage …

The ability of transcription factors to discriminate between different classes of binding sites
associated with specific biological functions underpins effective gene regulation in …

A major challenge in anticancer treatment is the pre-existence or emergence of resistance to
therapy. AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor …

Breast cancer (BC) is the leading cause of cancer death in women. This disease is
heterogeneous, with clinical subtypes being estrogen receptor-α (ER-α) positive, having …